Skip to content
Clinical Trials – home
CroatiaBack to Croatia

Clinical trials in Strmec Samoborski – page 16

259 clinical trials in Strmec Samoborski, Croatia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Strmec Samoborski at a glance
259
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

259 trials in Strmec Samoborski

Open in trial search

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Study on Fenebrutinib for Patients with Relapsing Multiple Sclerosis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Abdominal infection+3

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Study on the Safety and Efficacy of RO7204239 and Risdiplam for Patients with Spinal Muscular Atrophy

Registered drug
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years
  • Sponsor:F. Hoffmann-La Roche AG

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Sparsentan and Dapagliflozin for Patients with Immunoglobulin A Nephropathy (IgAN)

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Travere Therapeutics Inc.

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:CroatiaCroatia
  • Participants:65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Irbesartan
  • Sponsor:Travere Therapeutics Inc.

Study on the Effects of ARO-APOC3 for Adults with Familial Chylomicronemia Syndrome

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Obexelimab
  • Sponsor:Zenas Biopharma (USA) LLC

Hodgkin's disease

Not recruiting

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:Fundacion Geltamo

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Strmec Samoborski

What the registry says about research in the country

01 Cardiovascular Research

Clinical trials focusing on hyperlipidaemia management and cardiovascular risk reduction are exploring innovative treatment approaches. The research aims to evaluate the effectiveness of different therapeutic strategies in lowering LDL-C levels for patients with high and very high cardiovascular disease risk.

  • Lipid Management
  • Cardiovascular Risk Reduction
  • Combination Therapy Assessment

These studies examine the comparative efficacy of statin therapy and combination treatments, with a particular focus on achieving specific cholesterol reduction targets in high-risk populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.